CLINICAL TRIAL

Best practice alert for the notification of patient HFrEF and recommended evidence-based therapies (NO drugs are being administered in this trial) for Heart Failure

Recruiting · 18+ · All Sexes · New Haven, CT

This study is evaluating whether an electronic health record alert can help improve the use of medications for heart failure.

See full description

About the trial for Heart Failure

Eligible Conditions
Hearth Failure With Reduced Ejection Fraction (HFrEF) · Heart Failure

Treatment Groups

This trial involves 2 different treatments. Best Practice Alert For The Notification Of Patient HFrEF And Recommended Evidence-based Therapies (NO Drugs Are Being Administered In This Trial) is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are not being studied for commercial purposes.

Main TreatmentA portion of participants receive this new treatment to see if it outperforms the control.
Best practice alert for the notification of patient HFrEF and recommended evidence-based therapies (NO drugs are being administered in this trial)
OTHER
Control TreatmentAnother portion of participants receive the standard treatment to act as a baseline.

Eligibility

This trial is for patients born any sex aged 18 and older. There are 5 eligibility criteria to participate in this trial as listed below.

Inclusion & Exclusion Checklist
Mark “yes” if the following statements are true for you:
Patient
The left ventricular ejection fraction is less than or equal to 40%. show original
Age 18 or over
View All
Odds of Eligibility
Unknown<50%
Be sure to apply to 2-3 other trials, as you have a low likelihood of qualifying for this one.Apply To This Trial
Similar Trials

Approximate Timelines

Please note that timelines for treatment and screening will vary by patient
Screening: ~3 weeks
Treatment: varies
Reporting: Assessed 6 months post-randomization
This trial has approximate timelines as follows: 3 weeks for initial screening, variable treatment timelines, and reporting: Assessed 6 months post-randomization.
View detailed reporting requirements
Trial Expert
Connect with the researchersHop on a 15 minute call & ask questions about:
- What options you have available- The pros & cons of this trial
- Whether you're likely to qualify- What the enrollment process looks like

Measurement Requirements

This trial is evaluating whether Best practice alert for the notification of patient HFrEF and recommended evidence-based therapies (NO drugs are being administered in this trial) will improve 1 primary outcome and 17 secondary outcomes in patients with Heart Failure. Measurement will happen over the course of Assessed from the date of randomization to the date of hospital admission, up to 30 days post-randomization.

Rate of 30-day hospital admission
ASSESSED FROM THE DATE OF RANDOMIZATION TO THE DATE OF HOSPITAL ADMISSION, UP TO 30 DAYS POST-RANDOMIZATION
Rate of 30-day all-cause emergency department visits
ASSESSED FROM THE DATE OF RANDOMIZATION TO THE DATE OF ED/ER ADMISSION, UP TO 30 DAYS POST-RANDOMIZATION
Percentage of patient on MRAs
ASSESSED FROM THE DATE OF RANDOMIZATION TO 30 DAYS POST-RANDOMIZATION
Assessed as the number of patients with a prescribed MRA
Percentage of patient on ACE inhibitors
ASSESSED FROM THE DATE OF RANDOMIZATION TO 30 DAYS POST-RANDOMIZATION
Assessed as the number of patients with a prescribed ACEi
Proportion of patients with HFrEF with an increase in prescribed HFrEF therapy
ASSESSED FROM THE DATE OF RANDOMIZATION TO 30 DAYS POST-RANDOMIZATION
Assessed as an increase in the number of prescribed targeted evidence-based therapies for HFrEF, including beta-blockers, ACEi, ARBs, ARNIs, MRAs, and SGLT2is.
Percentage of patient on SGLT2 inhibitors
ASSESSED FROM THE DATE OF RANDOMIZATION TO 30 DAYS POST-RANDOMIZATION
Assessed as the number of patients with a prescribed SGLT2i
See More

Patient Q & A Section

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are the signs of heart failure?

The combination of a systolic BP below 90/60 mm Hg on repeated measurement and/or an atrial contraction that is lower than 5/15 cm2/min/ml or lower than 15% of that predicted on the basis of age, height and sex are clinically significant. An abnormal ECG, with signs of heart failure, justifies a further workup.

Anonymous Patient Answer

Can heart failure be cured?

Survival can't be predicted by HF status at initial diagnosis nor by HF trajectory during follow-up. Survival can, however, be predicted by age and the presence or absence of AF at initial diagnosis.

Anonymous Patient Answer

What is heart failure?

Heart failure, the fourth leading cause of death in the United States, is a complex and debilitating disorder associated with poor prognosis and high risk of death. It results from heart failure and cardiac remodeling after cardiac insult. Currently, the management of heart failure has not produced any significant changes in prognosis since the late 1970s. A more comprehensive management of heart failure and heart injury, and better understanding of the molecular basis underpinning their pathogenesis, is required for a meaningful improvement in the outcome of patients with heart failure.

Anonymous Patient Answer

What causes heart failure?

The exact cause of many heart failure cases is unknown. Although heart failure can be triggered by various types of disease, some triggers are clearly determined and controllable.\n

Anonymous Patient Answer

What are common treatments for heart failure?

Patients with heart failure and their carers benefit from education, medication management and support in order to maintain well-being and self-care. Exercise or cardiac rehabilitation may be used as alternatives to artificial support in addition to medication. When pharmacological therapy does not meet needs, many clinicians prefer pacing as the treatment of first choice. The importance and choice of treatment choices are more nuanced than can be predicted by health statistics, clinical practice guidelines or official treatment guidelines.

Anonymous Patient Answer

How many people get heart failure a year in the United States?

An estimated 5.7 percent (1.5 million) of Americans were hospitalized for heart failure in 1999, and 2.9 percent (773,000) died of the disease for a total of 10.2 percent. Heart failure occurred with slightly more frequency in women. Age was associated with more recent hospitalizations for heart failure, but not with mortality.

Anonymous Patient Answer

How does best practice alert for the notification of patient hfref and recommended evidence-based therapies (no drugs are being administered in this trial) work?

This trial demonstrates that alerts are indeed effective in identifying patients for optimal interventions and may also support health care providers as they establish rational and systematic practices to enhance the dissemination of evidence-based therapies.

Anonymous Patient Answer

Have there been any new discoveries for treating heart failure?

Pharmacological approaches aimed at treating acute heart failure have resulted in little change. The current pharmacological approaches have failed to show conclusive evidence that ACE inhibition and angiotensin receptor blockers, or digoxin, have any benefit in prolonging survival following a heart attack. A long-term trial comparing angiotensin receptor blocker with carvedilol, showed long-term benefit in those taking the angiotensin receptor agent. In particular, the results showed increased event-free survival (that is, a lack of heart attack, arrhythmias, stroke and death) in those following the angiotensin blocker compared with those on a carvedilol.

Anonymous Patient Answer

Who should consider clinical trials for heart failure?

The main criterion for trial eligibility should be an increase in life expectancy of ≥2 yr. If the condition is already in clinical remission, additional treatment is justified. If it is not in clinical remission, there should be some improvement before a clinical trial is indicated for the condition. People with severe symptoms related to the condition and/or a history of malignant arrhythmias should not undergo a trial.

Anonymous Patient Answer

Does best practice alert for the notification of patient hfref and recommended evidence-based therapies (no drugs are being administered in this trial) improve quality of life for those with heart failure?

An active educational approach aimed at all healthcare providers resulted in improvements in both HF and CHF patients in terms of quality of life. In addition, the active educational approach was accompanied by the improvement in the knowledge and compliance of some of the healthcare providers and resulted in significant improvements in the HF and CHF patients with respect to the quality of life.

Anonymous Patient Answer

Is best practice alert for the notification of patient hfref and recommended evidence-based therapies (no drugs are being administered in this trial) safe for people?

There were few breaches of best practice alert in patients with HF, the majority of whom did not receive medication. There was a high rate of evidence-based prescribing practices.

Anonymous Patient Answer

What is the primary cause of heart failure?

In patients with unexplained symptoms of heart failure, the cause of heart failure is less commonly identifiable than often thought. The most frequent causes of heart failure are the consequence of chronic coronary artery disease or idiopathic (having no known cause). The causes of heart failure in these patients can be defined as either the consequence of left ventricular dysfunction or, more seldom, as an incorrect referral. When causes are identified, it is often possible to select the appropriate treatment and the prognosis is usually excellent; however, treatment may be difficult or even impossible in some instances because the underlying cause is refractory to treatment.

Anonymous Patient Answer
See if you qualify for this trial
Get access to this novel treatment for Heart Failure by sharing your contact details with the study coordinator.